Lenalidomid Zentiva

Lenalidomide, the active ingredient in Lenalidomid Zentiva, is an Immunomodulatory imide drug (IMiD) presented as an oral tablet for oral use. It is indicated for the treatment of certain blood cancers, including multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma, and is prescribed for adult patients under specialist supervision.

GNH USA supplies Lenalidomid Zentiva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance.

Lenalidomide is used in hematologic malignancies, targeting abnormal plasma cells and dysplastic bone‑marrow clones.

Multiple Myeloma: reduces disease progression and improves survival in patients with relapsed or refractory disease. Myelodysplastic Syndromes with del(5q): induces transfusion independence and cytogenetic remission. Mantle Cell Lymphoma: provides disease control in patients who have received prior therapies.

Lenalidomide may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Fatigue: feeling of tiredness or lack of energy. - Diarrhea: loose, watery stools. - Nausea: sensation of queasiness. - Rash: skin redness or irritation.

Serious or Rare Side Effects: - Thromboembolic events: deep vein thrombosis or pulmonary embolism. - Severe neutropenia: marked reduction in neutrophil count increasing infection risk. - Secondary primary malignancies: emergence of new cancers unrelated to the original disease.

Before initiating therapy, clinicians should evaluate patient‑specific risk factors and monitor for potential complications.

- Monitor blood counts: regular CBC testing to detect cytopenias. - Assess thrombotic risk: evaluate need for prophylactic anticoagulation. - Avoid in pregnancy: teratogenic; ensure effective contraception. - Adjust for renal impairment: dose modifications may be required based on kidney function. - Counsel on infection signs: report fevers or infections promptly. - Store at ambient temperature: keep below 25 °C, in original container, protect from moisture and light.

Lenalidomid Zentiva can interact with several medicines, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce lenalidomide exposure. - Anticoagulants (warfarin, DOACs): increased risk of thrombosis or bleeding when combined with lenalidomide. - Live vaccines: heightened risk of infection due to immunosuppression.

Moderate Interactions (Monitor Closely): - P‑glycoprotein inhibitors (e.g., verapamil): may increase plasma levels. - NSAIDs: additive risk of renal impairment and gastrointestinal bleeding.